Arlene Chan

18.7k citations

144 papers · 6.8k indexed · 2 hit papers · h-index 30

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
Cancer Research top 0.5%
- Breast Cancer Treatment Studies

Papers in

Oncology 122
- Cancer Treatment and Pharmacology 71
- HER2/EGFR in Cancer Research 68
- Colorectal Cancer Treatments and Studies 16
Cancer Research 36
- Breast Cancer Treatment Studies 33

Co-authors: John Crown Bella Kaufman Stephen Chan Tadeusz Pieńkowski Mario Campone Charles E. Geyer Steven Stein David Cameron
Journals: Journal of Clinical Oncology (36 papers)Annals of Oncology (21 papers)Cancer Research (20 papers)Clinical Breast Cancer (4 papers)British Journal of Cancer (4 papers)
Partner nations: Australia United States France

In The Last Decade

Arlene Chan

142 papers receiving 6.6k citations

Hit Papers

align trajectories log scale

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer 2010 · 700 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Journal of Clinical Oncology
2006 New England Journal of Medicine

Peers

Countries citing papers authored by Arlene Chan

Since Specialization

Citations

This map shows the geographic impact of Arlene Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arlene Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arlene Chan more than expected).

Fields of papers citing papers by Arlene Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arlene Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arlene Chan. The network helps show where Arlene Chan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Arlene Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arlene Chan Line = papers co-authored together Arlene Chan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial Clinical Cancer Research ·Peter A. Fasching, Dennis J. Slamon, Zbigniew Nowecki, Wulan Ratnasari, Daniil Stroyakovskiy, DA Yardley, Chiun‐Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín, Hope S. Rugo, Sherene Loi, Sara A. Hurvitz, Michael Untch, Karen Afenjar, Rodrigo Fresco, Andriy Danyliv, 진명구, И. А. Тюрин, Gabriel N. Hortobágyi	2025	2
2	Abstract PS15-04: A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients Cancer Research ·Arlene Chan, Daphne Day, Phuong Dinh, هالة محمد عبد, Janine Lombard, Tae Hyuk Lee, Nicole McCarthy, Rosalind Wilson, Heidi B. Nafda, 健丹呉, Caitlin C. Murphy	2024	3
3	Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer JCO Precision Oncology ·Arlene Chan, Kyoungwoo Park, HuiJun Chih, M.P. Roessingh, 柏原俊秀, Pieter J.A. Eichhorn	2024	2
4	Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases ESMO Open ·J. Randolph Hecht, Steven S. Raman, Arlene Chan, Kevin Kalinsky, Jean‐François Baurain, M.M. Jimenez, Maria Martinez‐García, Martin D. Berger, Ulrich M. Lauer, A.O. Smith, Alfredo Carrato, Yue Zhang, Asrulla, Edward Cha, Alissa Keegan, Sumita Bhatta, Franko Gergorić, Aflah Roohullah	2023	22
5	AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Journal of Clinical Oncology ·Sara M. Tolaney, Arlene Chan, Katarína Petráková, Suzette Delaloge, Mario Campone, Hiroji Iwata, Parvin F. Peddi, Peter A. Kaufman, 北川仁美, Qianying Liu, Patrick Cohen, Gautier Paux, Lei Wang, Nils Ternès, Eric Boitier, Seock‐Ah Im	2023	37
6	73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial Annals of Oncology ·Arlene Chan, Manuel Ruíz Borrego, Gavin Marx, Adam Brufsky, شیوا اسلامیان کوپائی, Michael P. Thirlwell, Oscar Rydsjö, Ron Bose, José Á. García-Sáenz, Muhammad Ali Moriyani, Barbara Pistilli, Johanna Wassermann, Marek Demko, M Yurchenko, C Singer, Tamara Didishvili, В. Ю. Траскин, Leanne McCulloch, Charlotte Godziewski	2022	1
7	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer British Journal of Cancer ·Howard A. Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock‐Ah Im, Stephen Chia, Francisco J. Esteva, Lowell L. Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez Lorenc, Denise A. Yardley	2021	52
8	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer Clinical Cancer Research ·Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, Pierfranco Conté, Véronique Dièras, Nancy U. Lin, 純子西周, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders	2020	144
9	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study The Breast ·Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michelino De Laurentiis, Francisco J. Esteva, Guy Jérusalem, Patrick Neven, Xavier Pivot, Giulia Bianchi, Miguel Martín, David Chandiwana, Wang Fangdong, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch	2020	27
10	Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer Future Oncology ·Hiroji Iwata, Norikazu Masuda, Sung‐Bae Kim, Kenichi Inoue, Yoshiaki Rai, Takashi Fujita, Joanne Chiu, Shoichiro Ohtani, Masato Takahashi, Toshiko Miyaki, Yen‐Shen Lu, Binghe Xu, Yoon Sim Yap, Anita Zarina Bustam, Bin Yao, Bo Zhang, Richard Bryce, Arlene Chan	2019	7
11	Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial Annals of Oncology ·Suzette Delaloge, Marise Lima Freire, David Cella, Marc Buyse, Arlene Chan, Carlos H. Barrios, Frankie A. Holmes, Janine Mansi, Hiroji Iwata, Bent Ejlertsen, Beverly Moy, Gϋnter von Minckwitz, Stephen Chia, Michael Gnant, Snezhana Smichkoska, Simon Bach, Susan Moran, Alan Auerbach, Lesley Fallowfield, M. Martín Jiménez	2017	2
12	Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer Clinical Breast Cancer ·Saverio Cinieri, Arlene Chan, Kadri Altundağ, A. Vandebroek, N. Tubiana-Mathieu, Agustí Barnadas, Bhoj Raj Ojha, Silvia Lazzarelli, Hee-young Son, Daniel Rauch, G. Villanova, Uğur Çoşkun	2016	8
13	Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer Clinical Cancer Research ·Tarek M. Abdel-Fatah, Graham Ball, Andrew H.S. Lee, Sarah E. Pinder, Samara Fortunato Cardoso, Eleanor Cornford, Paul M. Moseley, Hyung-Ju Na, 长春长春师范大学吉林, Richard A. Nida, D. M. Palmer, Arlene Chan, Ian O. Ellis, Stephen Chan	2014	14
14	Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer Journal of Clinical Oncology ·José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada	2013	298
15	Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. PubMed ·Arlene Chan, Pierfranco Conté, Luboš Petruželka, N. Tubiana-Mathieu, Vinod Ganju, Antonio Llombart‐Cussac, Marc Espié, F. Majois, Miguel Gil Gil, Nathalie Vaissière, G. Villanova	2013	6
16	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer Journal of Clinical Oncology ·Luca Gianni, Gilles Romieu, М. Р. Личиницер, Sérgio Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice André, Arlene Chan, Oleg Lipatov, Stephen Chan, Andrew Wardley, Richard Greil, N. Moore, Ae Kyung Kim, Céline Pallaud, Semiglazov Vf	2013	199
17	Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study The Oncologist ·Heather‐Jane Au, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, John Crown, Miguel Martín, Marek Pawlicki, Arlene Chan, John R. Mackey, John A. Glaspy, Tamás Pintér, Mei-Ching Liu, Tommy� Fornander, Sandeep Sehdev, Jean-Marc Ferrero, Valerie Bée, Maria Santana, Dave P. Miller, Deepa Lalla, Dennis J. Slamon	2013	19
18	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Journal of Clinical Oncology ·Antonio C. Wolff, Ann Lazar, Igor Bondarenko, August Garin, Stephen Brincat, Louis W.C. Chow, Yan Sun, Zora Nešković‐Konstantinović, Rodrigo C. Guimarães, P. Fumoleau, Arlene Chan, 元板坂, Andrew Strahs, Maria Cincotta, Anna Berkenblit, Mizue Krygowski, Hery Kristanto, Laurence Moore, Daniel F. Hayes	2012	222
19	Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib Japanese Journal of Clinical Oncology ·Charles Vogel, Arlene Chan, Brunilde Gril, G G Dellar, М.Г. Пименов, Li Liu, Yen‐Shen Lu, Dalia Abd-Elghany El Khodary	2010	19
20	A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Annals of Oncology ·Xavier Pivot, P. Koralewski, Jorge Hidalgo, Arlene Chan, Anthony Gonçalvès, Gilberto Schwartsmann, Sylvie Assadourian, Jean‐Pierre Lotz	2008	148

About Arlene Chan

Arlene Chan is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 144 papers that have together received 6.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (71 papers), HER2/EGFR in Cancer Research (68 papers), Advanced Breast Cancer Therapies (62 papers), Breast Cancer Treatment Studies (33 papers), Colorectal Cancer Treatments and Studies (16 papers), Chronic Lymphocytic Leukemia Research (12 papers), Gastric Cancer Management and Outcomes (10 papers) and Estrogen and related hormone effects (7 papers). The work is most often cited by research in Oncology (5.4k citations), Cancer Research (1.7k citations), Pulmonary and Respiratory Medicine (2.3k citations), Genetics (571 citations) and Radiology, Nuclear Medicine and Imaging (1.1k citations). Arlene Chan has collaborated with scholars based in Australia, United States and France. Frequent co-authors include John Crown, Bella Kaufman, Stephen Chan, Tadeusz Pieńkowski, Mario Campone, Charles E. Geyer, Steven Stein, David Cameron, Dimosthenis Skarlos and Stephen D. Rubin. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Breast Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact